STOKE THERAPEUTICS INC

Company Overview

Stoke Therapeutics (Healthcare; Biotechnology) is a late‑stage RNA‑based biotech developing antisense oligonucleotide therapies using its TANGO platform to upregulate protein expression for haploinsufficiency disorders. The lead asset, zorevunersen (STK‑1001) for Dravet syndrome, moved into the pivotal Phase 3 EMPEROR study in 2025 (first patient dosed Aug 2025) with a pivotal readout expected in H2 2027; other programs include STK‑1002 (OPA1/ADOA) and earlier CNS/ocular programs. The company is R&D‑centric (128 employees, ~40 MD/PhDs), relies on CMOs for manufacturing, and has material near‑term value drivers in EMPEROR enrollment/readouts, OLE durability/safety data, and partnered milestones (notably the Feb 2025 Biogen collaboration).

Executive Compensation Practices

As a pre‑commercial, late‑stage biotech, Stoke’s compensation mix is likely equity‑heavy with meaningful stock‑based awards and retention grants to conserve cash while aligning executives with long‑dated clinical milestones (EMPORER start/readout, OLE outcomes, and partnership milestones). Filings show rising stock‑based compensation and increased G&A/R&D headcount costs, indicating equity awards are already a material component of pay; short‑term cash bonuses are likely tied to clinical/partnership milestones and organizational growth metrics. Given the Biogen 70/30 development cost‑sharing and sizable upfront payment ($165M) that extended runway to mid‑2028, management pay plans may emphasize milestone achievement, regulatory interactions, and commercialization readiness while using phased retention awards to secure specialized RNA talent.

Insider Trading Considerations

Insiders will be tightly constrained around material events typical for the Biotechnology/Pharmaceutical Products industry — trial starts, interim analyses, pivotal readouts, regulatory meetings, and milestone recognitions (ASC 606 timing matters) — so watch for blackout windows and Form 4 filings clustering just after public announcements. Because the company frequently uses equity for compensation and has an active S‑3 shelf (effective July 11, 2025) and recent financings, insider selling can occur for diversification or tax reasons but often follows public milestone/collaboration news (e.g., Biogen upfront recognition); 10b5‑1 plans are common in this sector to provide predictable sales cadence. Regulatory and contractual restrictions (collaboration lock‑ups, Section 16 reporting) plus the sensitivity of trial data mean any unexpected or large insider trades around clinical or milestone events can attract investor scrutiny; monitor Form 4 timing relative to EMPEROR enrollment updates, OLE data releases, and Biogen milestone announcements.